

PRESS RELEASE

Axio Biosolutions receives another FDA clearance for Axiostat Patch for Vascular Bleeding Control

- Clearance granted several months ahead of the initial schedule
- Launch in the United States expected by early 2022

Bengaluru, 30th June 2021: Axio Biosolutions, an integrated wound care company has announced FDA 510(k) clearance of its hemostatic product, Axiostat Patch that helps control moderate to severe bleeding in vascular procedures, surgical debridement sites, puncture sites and more.

Axiostat Hemostatic Patch is based on a protonated bioadhesive technology which works by providing a strong mechanical barrier to the injury site. It controls bleeding from puncture sites within minutes of application, providing a barrier to bacteria protection while reducing the ambulation time in patients significantly.

Axiostat had also received CE mark in Europe earlier and is approved in over 40 countries worldwide. Over half a million units have been deployed since inception globally especially in battlefields to control bleeding from trauma injuries and in hospitals to control for vascular closure bleeding.

Commenting on the latest development, **Leo Mavelly, Founder & CEO, Axio Biosolutions** said, “This is a major milestone for us as the FDA clearance opens the door for us to enter markets such as Cardio-vascular, Hemodialysis and Military bleeding control in the US. Axiostat is already a market leader for these in many countries and we intend to bring this technology to the US customers very soon.”

About Axio Biosolutions

Axio was founded in 2008 and develops novel biomaterial-based products for wound and surgical care. Axio’s flagship product Axiostat that stops bleeding instantly is regularly used by many armed forces globally including Indian armed forces, BSF, NSG, and other para-military forces, as part of their trauma kits. Axio’s products are sold in over 40 countries and over 400 top hospitals in India such as AIIMS, Manipal, Apollo, Breach Candy and Fortis, among others. Axio has raised over \$15 million from Accel, University of California - Ratan Tata (UC-RNT) Fund, Omidyar Network India, and Chiratae Ventures.

Axio is one of the largest chitosan medical products manufacturer globally and has a state-of-the-art manufacturing facility at Ahmedabad, India which is GMP, ISO 13485 certified and registered with USFDA.

For more info, visit: www.axiobio.com.

For enquiries: info@axiobio.com

Phone: +91 88607 86067